TTLL13 Inhibitors
TTLL13 inhibitors belong to a specialized class of chemical compounds that target and inhibit the function of the enzyme TTLL13 (tubulin tyrosine ligase-like family member 13). The TTLL family of enzymes plays a critical role in the post-translational modification of proteins, specifically through the addition of polyglutamate (polyGlu) chains to target proteins, which is a process known as polyglutamylation. Polyglutamylation is a reversible modification that occurs predominantly on tubulin, the primary building block of microtubules, and is known to influence the stability and dynamics of the microtubule network within the cell. TTLL13, in particular, is one of the enzymes responsible for this post-translational modification and is involved in the regulation of the cellular machinery.
The inhibitors designed to target TTLL13 are molecular entities that bind to the active site of the enzyme or to allosteric sites, thereby preventing the enzyme from performing its catalytic function of adding polyGlu chains. This inhibition can affect the normal functioning of microtubules and, as a result, have an impact on various cellular processes such as cell division, intracellular transport, and cellular architecture. The design of TTLL13 inhibitors often involves the use of high-throughput screening techniques to identify potential inhibitory compounds, followed by iterative cycles of medicinal chemistry to optimize their selectivity and potency. By blocking TTLL13's activity, these inhibitors modulate the level of polyglutamylation, providing a tool for understanding the biological role of this modification in cellular processes. As such, the study of TTLL13 inhibitors is a significant area of interest for researchers looking to elucidate the complex interplay between post-translational modifications and cellular function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. By inhibiting these kinases, the cell cycle is arrested in the G1 phase, which could indirectly reduce the activity of TTLL13 if it is involved in processes linked to cell cycle progression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor. It alters chromatin structure and function, potentially downregulating TTLL13 expression if TTLL13 is regulated by histone acetylation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Accumulation of proteins may disrupt various cellular processes, potentially decreasing TTLL13 activity if it relies on proteasome-mediated regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that leads to the inhibition of the AKT signaling pathway. If TTLL13 is regulated by AKT signaling, LY294002 could reduce its activity through this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTOR signaling pathway, which is critical for cell growth and survival. TTLL13 activity could be reduced if it is associated with mTOR-dependent processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that blocks the MAPK/ERK signaling pathway. If TTLL13 functions downstream or is modulated by the MAPK/ERK pathway, U0126 could decrease its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can suppress inflammatory responses and cell differentiation. This could lead to a decrease in TTLL13 activity if it is part of these cellular responses. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 is an inhibitor of the vacuolar-type H+ ATPase (V-ATPase) and can disrupt endosome/lysosome acidification and autophagy. TTLL13 may be inhibited if it is involved in autophagic processes. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
WZB117 is a GLUT1 inhibitor that prevents glucose uptake. If TTLL13 activity is related to cellular metabolism and energy homeostasis, WZB117 could indirectly inhibit TTLL13 by limiting energy supply. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which blocks the MAPK/ERK pathway. If TTLL13 is modulated by this pathway, inhibition by PD98059 could reduce TTLL13 activity. | ||||||